Michael Finney
Managing Director at Finney Capital
Michael Finney
Managing Director at Finney Capital
San Francisco, California
Overview
Work Experience
Board Chair
2023 - Current
Member Board of Directors
2007
Interim Chief Executive Officer
2024 - 2024
I've served on the Board of Directors since 2007, became Chair in 2023, and Interim CEO in January 2024. Previously, I served as CEO for over two years, July 2009 to October 2011. Vaxart is a game-changing company with its technology for oral vaccination, and has an excellent team.
CEO
2009 - 2011
Having served on the board since 2007, in 2009 I came in as acting CEO and ended up staying over 2 years. In this time, we closed a $12 million Series B, completed preclinical work, ran a Phase I clinical trial, and hired a permanent CEO.
Board Chair
2014
Director
2019
Enabling single-cell genomics for solid tissues
Board Chair
2019
Commercializing technology from the Collins lab at UC Berkeley
Managing Director
2004
Director
2016
Reagent systems for DNA sequencing
Director
1998
Board Chair
2005
Board Chair, December 2015-present
Director and Permanent Member
1999
Formerly named G Corp, TGP is a non-profit corporation that is responsible for, among other things, the AGBT Genomics meeting. The meeting has been held every February since 2000. It provides an opportunity for academics and commercial companies in the field of genomics to exchange the latest advances.
Member
2006
Education
AB
1976 - 1980
Ph.D.
1980 - 1987
Stanford Directors' College
2015 - 2015